Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Completed 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 120Tumor-Agnostic 3Other 2Gynecologic 2Endocrine 2

Conditions

Ovarian Neoplasms 1Granulosa Cell Ovarian Cancer 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Anastrozole × Gynecologic × Clear all
NCT03909152 2025-07-28

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
34 enrolled 9 charts
Gynecologic

Granulosa Cell Ovarian Cancer

NCT00181688 2012-12-05

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

Massachusetts General Hospital

Phase 2 Completed
35 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡